Micromet's cancer drug portfolio draws big drugmakers' attention

06/14/2010 | Bloomberg Businessweek

Biotech firm Micromet was able to secure a partnership with major drugmakers, including Bayer and Boehringer Ingelheim, because of its line of cancer treatments that might boost the effectiveness of rival medicines. Blinatumomab, Micromet's drug candidate for acute lymphocytic leukemia, led to complete remission during a clinical trial in about 80% of patients who still had leukemia cells after undergoing different forms of chemotherapy.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA